Logo

Maravai LifeSciences Acquires Glen Research

Jan 03, 2018 | staff reporter

NEW YORK (GenomeWeb) – Maravai LifeSciences announced today that it has acquired Glen Research, a Virginia-based provider of DNA and RNA synthesis reagents.

Specific terms of the deal were not disclosed.

"The acquisition supports our commitment to the genomics market, which we first entered with the acquisition of TriLink BioTechnologies," Maravai President Eric Tardif said in a statement. Maravai acquired TriLink in 2016.

Maravai was launched in 2014 by private equity firm GTCR in partnership with Tardif and Carl Hull, two former Gen-Probe executives. In addition to TriLink, the company also recently acquired analytical product supplier Cygnus Technologies and made a strategic equity investment in life science tools firm Vector Laboratories.

Filed under

Business News
Tools & Technology
mergers & acquisitions
DNA synthesis
reagents
Breaking News
The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.